Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “A key debate on Arcutis’ lead asset, topical roflumilast, has been on its market potential given the likely difficult formulary environment and cheaper generic treatments. We surveyed 20 high-volume dermatologists and, based on our proprietary work, we believe topical roflumilast has blockbuster potential given the potential best-in-class profile in three large topical dermatological markets (psoriasis, atopic dermatitis, and seborrheic dermatitis). We model risk-adjusted total roflumilast revenues of $1.42Bn in 2030 that will likely increase to >$2Bn (unadj) as the clinical programs mature. However, at the current stock price, we believe the market is assigning a significantly lower value, setting up ARQT nicely to appreciate as multiple key catalysts play out in the next 12-18 months.”
To request access to the full report, visit http://nnw.fm/SaZ9d
About Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a medical dermatology company that champions meaningful innovation to address the urgent needs of patients living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis harnesses our unique dermatology development platform coupled with our dermatology expertise to build differentiated therapies against biologically validated targets. Arcutis’ dermatology development platform includes a robust pipeline with seven clinical programs for a range of inflammatory dermatological conditions, with our first NDA submission by the end of 2021 and three more Phase 3 clinical data readouts anticipated over the next 18 months. The company’s lead product candidate, topical roflumilast, has the potential to advance the standard of care for plaque psoriasis, atopic dermatitis, scalp psoriasis, and seborrheic dermatitis. For more information, visit www.arcutis.com.
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.networknewswire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
[email protected]
NetworkNewsWire is part of the InvestorBrandNetwork
